Akero Therapeutics Removed from S&P TMI Index Amid MASH Treatment Development
ByAinvest
Wednesday, Dec 10, 2025 7:25 pm ET1min read
AKRO--
Akero Therapeutics has been dropped from the S&P TMI Index. The company is a clinical-stage biotech developing treatments for metabolic diseases, with its lead product candidate, Efruxifermin (EFX), being evaluated in phase IIb and III trials for MASH, a disease with no approved therapies. EFX is an analog of the hormone FGF21, which regulates metabolism and protects against cellular stress.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet